Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734067 | 0.83 | ALDH1A1 (0.58) | ALDH1A1PKMATMHSD17B10CYP1A2 | |
| SCHEMBL7507722 | 0.77 | PKM (0.68) | ALDH1A1PKMATMHSD17B10MAPT | |
| SCHEMBL18623451 | 0.76 | PKM (0.75) | ALDH1A1PKMATMHSD17B10CYP1A2 | |
| SCHEMBL14145932 | 0.72 | PKM (0.79) | ALDH1A1PKMATMHSD17B10MAPT | |
| SCHEMBL14641240 | 0.72 | HSD17B10 (0.79) | ALDH1A1PKMATMHSD17B10CYP1A2 | |
| SCHEMBL29328610 | 0.72 | GAA (0.52) | ALDH1A1CYP4F2CYP4A11GAATNF | |
| SCHEMBL23069273 | 0.71 | ALDH1A1 (0.42) | ALDH1A1HSD17B10CYP1A2CYP4F2CYP4A11 | |
| SCHEMBL10965121 | 0.70 | ALDH1A1 (0.49) | ALDH1A1HSD17B10CYP1A2GAATNF | |
| SCHEMBL5965096 | 0.69 | ALDH1A1 (0.45) | ALDH1A1CYP1A2GAATNFMAPT | |
| SCHEMBL7507085 | 0.69 | PKM (0.68) | ALDH1A1PKMATMHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829580-B2 | Cyclic amine derivative having heteroaryl ring | SANKYO COMPANY, LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| CN-1910151-A | Cyclic amine derivative with heteroaryl ring | SANKYO CO (JP) | 2007-02-07 | — | — | CN | disclosed |
| US-20060270706-A1 | Cyclic amine derivative having heteroaryl ring | SANKYO COMPANY, LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1695962-A1 | CYCLIC AMINE DERIVATIVE HAVING HETEROARYL RING | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270706-A1 | Cyclic amine derivative having heteroaryl ring | F12, F2, H1-3 | ALDH1A1 1073/4885PKM 3626/4885ATM 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.